8-K: HeartSciences Reports Q1 FY27 Results, Merger Progress

HeartSciences Inc. reported fiscal first quarter 2027 results, highlighting progress on its proposed merger with Fortitude Mining Holdings, Inc. and a strategic shift towards its MyoVista Insights platform.

Summary

• HeartSciences reported financial results for its fiscal first quarter ended July 31, 2026 (FQ1 2027).
• The company is progressing with its proposed business combination with Fortitude Mining Holdings, Inc., with an expected closing in Q4 calendar 2026.
• Commercial efforts are focused on the MyoVista Insights platform, with the first US commercial agreements signed and selection as an AI-ECG delivery platform for a European reference center.
• The company has recorded a $0.3 million reserve against the carrying value of MyoVista wavECG device inventory and does not intend to commit significant resources to its commercialization.
• Loss from operations for FQ1 2027 was $2.9 million, an increase from $1.9 million in FQ1 2026, impacted by merger-related costs, share-based compensation, and the inventory reserve.
• Net loss for FQ1 2027 was $3.2 million, compared to $2.1 million in FQ1 2026.
• As of July 31, 2026, the company had a shareholders deficit of $2.0 million.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, balancing progress on a significant merger with operational challenges and a strategic pivot away from a product.

Positives

• The proposed business combination with Fortitude Mining Holdings, Inc. continues to progress, with an expected closing in Q4 calendar 2026.
• Fortitude has made significant operational developments, including executing a purchase agreement for 9,000 Z15 Pro miners and energizing its 12 MW facility in Grand Island, Nebraska.
• Fortitude also acquired a 12.5 MW facility in Prosser, Nebraska.
• Fortitude subscribed for approximately $1.0 million of HeartSciences common stock in August 2026.
• HeartSciences has signed its first US commercial agreements for the MyoVista Insights platform.
• MyoVista Insights has been selected as the ECG management and AI-ECG delivery platform for a clinical program at a major European reference center.
• The company's patent portfolio has expanded, with over 45 granted patents, including a European patent for ECG-based assessment of diastolic function.
• Feedback from clinicians and health systems on MyoVista Insights has been consistently positive.

Negatives

• HeartSciences reported no meaningful revenue for FQ1 2027.
• The loss from operations increased to $2.9 million in FQ1 2027 from $1.9 million in FQ1 2026.
• The net loss for FQ1 2027 was $3.2 million, compared to $2.1 million in FQ1 2026.
• The company has a shareholders deficit of $2.0 million as of July 31, 2026.
• A $0.3 million reserve has been recorded against the carrying value of MyoVista wavECG device inventory.
• The company does not intend to commit significant additional resources to the commercialization of the MyoVista wavECG device.
• The FDA 510(k) submission for the MyoVista wavECG device remains under FDA review, but does not include the necessary AI algorithm for commercialization.
• The timeline to commercialization for the MyoVista wavECG device cannot currently be established.

Risks

• The risk that the Proposed Transaction may not be completed on the anticipated timeline or at all.
• The failure to satisfy the conditions to the closing of the Proposed Transaction, including obtaining the requisite approval of HeartSciences shareholders.
• Market, macroeconomic, or other conditions that could adversely affect either HeartSciences or Fortitude, or the combined company.
• Risks related to the integration of the two companies and the management of a newly public company.
• Risks relating to Fortitudes operations and business, including the highly volatile nature of the price of Zcash and other cryptocurrencies.
• Risks relating to significant legal, commercial, regulatory and technical uncertainty regarding digital assets generally.
• Risks relating to the commercialization of MyoVista Insights, including the rate of adoption by healthcare providers and the conversion of agreements into revenue.
• Risks relating to the MyoVista wavECG device, including the timing and outcome of the pending FDA 510(k) submission and the recoverability of the related inventory.

Future Outlook

The company expects to close the proposed business combination with Fortitude in Q4 calendar 2026. Commercial progress is anticipated for MyoVista Insights in the year ahead, with a focus on execution and delivery. The commercialization timeline for the MyoVista wavECG device is uncertain.

Management Comments

• "The proposed combination with Fortitude is expected to give our shareholders exposure to a business that is a meaningful participant in the Zcash ecosystem. In our view, it represents a significant opportunity for shareholders and the transaction continues to move toward closing."
• "We believe MyoVista Insights offers a best-in-class, cloud-native, vendorand device-agnostic ECG management platform designed to modernize ECG workflows and enable scalable deployment of AI-ECG capabilities across healthcare systems."
• "The response from the clinicians using it has been excellent. We have signed our first commercial agreements in the United States, we have been selected as the delivery platform for a clinical program at a leading European reference center, and the AI-ECG marketplace is attracting developers that recognize it as a route to deliver their models directly into clinical workflows at scale."
• "We expect significant commercial progress in the year ahead and our efforts are focused on execution and delivery."

Industry Context

StockSavvy.ai notes that HeartSciences is navigating a significant strategic shift, moving away from a proprietary hardware device towards a software and AI-driven platform (MyoVista Insights) in the healthcare IT sector. This aligns with broader industry trends favoring cloud-based solutions and AI integration. The proposed merger with Fortitude, a digital asset mining company, introduces exposure to the cryptocurrency ecosystem, specifically Zcash, which has seen recent institutional interest. This diversification strategy is notable in the current market.

Related Party Transactions

• Fortitude, a party to the proposed merger, subscribed for approximately $1.0 million of HeartSciences common stock in August 2026. The exchange ratio under the merger agreement was not adjusted as a result, and no additional shares will be issued to Fortitude at closing in respect of this investment.

Stakeholder Impact

• Shareholders: The proposed merger with Fortitude offers potential exposure to the Zcash ecosystem. The strategic shift away from the MyoVista wavECG device may impact the perceived value of existing inventory.
• Employees: The company's focus on MyoVista Insights and the merger integration will likely influence resource allocation and strategic priorities.
• Customers: The selection of MyoVista Insights by a European reference center indicates potential for broader adoption in healthcare systems.
• Creditors: The company's financial condition, including its shareholders deficit, may be a consideration for creditors.

Next Steps

• Closing the proposed business combination with Fortitude, subject to customary closing conditions and shareholder approval.
• Continuing to concentrate commercial efforts on the MyoVista Insights platform.
• Expanding the number of AI-ECG algorithms available through the AI-ECG marketplace.
• Building relationships with key reference centers.
• Focusing on execution and delivery for commercial progress.
• The FDA 510(k) submission for the MyoVista wavECG device remains under FDA review, though commercialization is not a current focus.

Key Dates

Recommendation

The filing presents a mixed picture. While progress on the Fortitude merger and initial commercial traction for MyoVista Insights are positive, the increased operational losses, shareholder deficit, and the strategic pivot away from the MyoVista wavECG device introduce significant uncertainty. The company's future performance is heavily reliant on the successful integration with Fortitude and the scaling of its software platform, which carries inherent risks. Therefore, a 'hold' recommendation is appropriate pending further clarity on the merger's closing and the commercial ramp-up of MyoVista Insights.

Keywords

HeartSciences, Fortitude Mining, Merger, MyoVista Insights, AI-ECG, Zcash, Electrocardiography, Digital Asset Mining